Highlights From NCCN

Updated NCCN Breast Cancer Guidelines

The updated guidelines from the National Comprehensive Cancer Network on the management of metastatic non–small cell lung cancer reflect the addition of osimertinib as a first-line option in patients with an epidermal growth factor receptor (EGFR)-sensitizing mutation and as subsequent therapy in patients whose disease progresses following another tyrosine kinase inhibitor if they develop a T790M resistance mutation.

The revised guideline (Version 2.2016) for the management of advanced melanoma, released by the National Comprehensive Cancer Network (NCCN), shows increasing appreciation for the use of immune checkpoint inhibitors and targeted agents, as more data establish these drug classes as having superior efficacy to traditional chemotherapy.

The population of patients with multiple myeloma (MM) who are eligible for therapy has been expanded to asymptomatic patients with certain features under the most recent National Comprehensive Cancer Network (NCCN) guideline (Version 3.2016).

Tyrosine kinase inhibitors (TKIs) are the mainstay of treatment for patients with EGFR mutation–positive non–small cell lung cancer (NSCLC), according to the most recent guideline on management of NSCLC issued by the National Comprehensive Cancer Network (NCCN).

The National Comprehensive Cancer Network (NCCN) provides clinical practice guidelines in oncology for all types and stages of cancer as well as areas of supportive care.

In March, the National Comprehensive Cancer Network (NCCN) guidelines for genetic/familial high-risk assessment for breast and ovarian cancers were updated. Among the updates is a section on “gene panels.”

The National Comprehensive Cancer Network^® (NCCN^®) is a nonprofit alliance of 21 of the world’s leading cancer centers.

On October 26, 2011, lung cancer screening guidelines were published by the National Comprehensive Cancer Network (NCCN).